​

BioCryst Pharmaceuticals (BCRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BCRX Stock Forecast

BioCryst Pharmaceuticals (BCRX) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $9.00, with a high of $11.00 and a low of $7.00. This represents a 12.22% increase from the last price of $8.02.

$4 $5 $6 $7 $8 $9 $10 $11 High: $11 Avg: $9 Low: $7 Last Closed Price: $8.02

BCRX Stock Rating

BioCryst Pharmaceuticals stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (80.00%), 3 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 3 12 Strong Sell Sell Hold Buy Strong Buy

BCRX Forecast vs Benchmarks

TypeNameUpside
StockBioCryst Pharmaceuticals12.22%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$9.00
Last Closing Price$8.02$8.02$8.02
Upside/Downside--12.22%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25641--11
Dec, 24641--11
Nov, 246521-14
Oct, 246821-17
Sep, 246821-17
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 06, 2024Gena WangBarclays$7.00$7.51-6.79%-12.72%
Aug 05, 2024Maury RaycroftJefferies$11.00$7.5146.47%37.16%
Nov 02, 2022Liisa BaykoEvercore ISI$16.00$12.3929.14%99.50%
Aug 23, 2022Gena WangBarclays$14.00$14.33-2.30%74.56%
Jan 10, 2022Ken CacciatoreCowen & Co.$25.00$14.7869.15%211.72%
Nov 03, 2021Brian ChengCantor Fitzgerald$21.00$12.4069.35%161.85%
Aug 09, 2021Maury RaycroftJefferies$19.00$17.657.65%136.91%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2024Piper SandlerOverweightOverweighthold
Nov 04, 2024Bank of America SecuritiesBuyBuyhold
Aug 06, 2024JMP SecuritiesOutperformOutperformhold
Aug 06, 2024BarclaysEqual-WeightEqual-Weighthold
Aug 05, 2024JefferiesBuyBuyhold
Jun 25, 2024Cowen & Co.BuyBuyhold
May 07, 2024JMP SecuritiesOutperformOutperformhold
Sep 18, 2023RBC CapitalOutperformupgrade
Aug 04, 2023William BlairMarket Performdowngrade
Aug 04, 2023JefferiesBuyupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.18$-1.03$-1.38$-1.18-----
Avg Forecast$-1.00$-1.22$-1.11$-1.05$-0.37$-0.09$0.27$0.74$0.97
High Forecast$-1.06$-1.29$-1.15$-1.23$-0.42$-0.32$0.13$0.25$0.95
Low Forecast$-0.90$-1.10$-1.05$-0.98$-0.29$0.16$0.38$1.17$0.98
Surprise %18.00%-15.57%24.32%12.38%-----

Revenue Forecast

$0 $170M $340M $510M $680M $850M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$17.81M$157.17M$270.83M$331.41M-----
Avg Forecast$28.56M$160.40M$265.41M$327.97M$449.34M$548.90M$628.83M$725.85M$810.41M
High Forecast$26.44M$148.50M$253.42M$325.16M$447.13M$547.52M$628.83M$720.86M$801.33M
Low Forecast$29.85M$167.64M$271.98M$333.03M$452.05M$551.10M$628.84M$730.83M$818.52M
Surprise %-37.63%-2.01%2.04%1.05%-----

Net Income Forecast

$-300M $-190M $-80M $30M $140M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-196.57M$-184.06M$-247.12M$-226.54M-----
Avg Forecast$-160.74M$-161.72M$-213.98M$-226.54M$-68.56M$-13.73M$49.07M$212.79M$185.47M
High Forecast$-192.88M$-194.06M$-220.87M$-271.85M$-81.53M$-61.50M$24.30M$47.93M$182.77M
Low Forecast$-128.59M$-129.37M$-201.42M$-181.23M$-55.59M$30.75M$73.83M$225.13M$187.88M
Surprise %22.29%13.82%15.49%------

BCRX Forecast FAQ

Is BioCryst Pharmaceuticals stock a buy?

BioCryst Pharmaceuticals stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioCryst Pharmaceuticals is a favorable investment for most analysts.

What is BioCryst Pharmaceuticals's price target?

BioCryst Pharmaceuticals's price target, set by 15 Wall Street analysts, averages $9 over the next 12 months. The price target range spans from $7 at the low end to $11 at the high end, suggesting a potential 12.22% change from the previous close price of $8.02.

How does BioCryst Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

BioCryst Pharmaceuticals stock forecast shows a 12.22% upside, underperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for BioCryst Pharmaceuticals over the past three months?

  • January 2025: 54.55% Strong Buy, 36.36% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 54.55% Strong Buy, 36.36% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 42.86% Strong Buy, 35.71% Buy, 14.29% Hold, 7.14% Sell, 0% Strong Sell.

What is BioCryst Pharmaceuticals’s EPS forecast?

BioCryst Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is -0.37 for 2024, a -68.64% decrease from the reported $-1.18 in 2023. The prediction for 2025 is $-0.09, $0.27 for 2026, $0.74 for 2027, and $0.97 for 2028.

What is BioCryst Pharmaceuticals’s revenue forecast?

BioCryst Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $449.34M for 2024, a 35.58% increase from the reported $331.41M in 2023. The forecast for 2025 is $548.9M, $628.83M for 2026, $725.85M for 2027, and $810.41M for 2028.

What is BioCryst Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, BioCryst Pharmaceuticals's average annual net income forecast is $-68.561M for 2024, reflecting a -69.74% decrease from the reported $-227M in 2023. The projection for 2025 is $-13.728M, $49.07M for 2026, $212.79M for 2027, and $185.47M for 2028.